Medline (MDLN) shares slipped for the fourth consecutive session on Wednesday after the FDA issued a warning letter regarding several manufacturing lapses at a companyâs production facility in Illinois.
The letter addressed to Medline (MDLN) CEO Jim Boyle followed Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities
Subscribe to Newsletters To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser